Boryung Corporation (KRX:003850)
South Korea · Delayed Price · Currency is KRW 8,610.00
+370.00 (4.49%)
At close: Nov 26, 2025
Boryung Revenue
Boryung had revenue of 251.52B KRW in the quarter ending June 30, 2025, a decrease of -1.58%. This brings the company's revenue in the last twelve months to 1.02T, up 9.83% year-over-year. In the year 2024, Boryung had annual revenue of 1.02T with 18.32% growth.
Revenue (ttm)
1.02T
Revenue Growth
+9.83%
P/S Ratio
0.71
Revenue / Employee
671.23M
Employees
1,533
Market Cap
727.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.02T | 157.48B | 18.32% |
| Dec 31, 2023 | 859.63B | 99.15B | 13.04% |
| Dec 31, 2022 | 760.48B | 133.20B | 21.23% |
| Dec 31, 2021 | 627.28B | 65.41B | 11.64% |
| Dec 31, 2020 | 561.87B | 37.60B | 7.17% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |